Hepatitis C, Chronic, Mixed Cryoglobulinemia
Conditions
Brief summary
Mixed cryoglobulinemia (MC) is common in patients with chronic hepatitis C virus (HCV) infection. Direct-acting antiviral (DAA) regimens are today very effective with sustained virological response rates (SVR12) above 90%. The objective of this study was to investigate the impact of DAA therapy on cryoglobulin clearance in patients with HCV-associated MC.
Detailed description
We focused on HCV patients with or without HIV with MC who had at least one cryoglobulin level assessment before and after DAA therapy and investigated the impact of DAA therapy on cryoglobulin clearance.
Interventions
DRUGDAA treatment
Patients were treated with direct-acting antiviral (DAA) treatment for 12 or 24 weeks
Sponsors
Hospices Civils de Lyon
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* hepatitis C virus (HCV) infected patients * symptomatic or asymptomatic mixed cryoglobulinemia * coinfected or not with HIV * treated by direct-acting antiviral (DAA) treatment * at least one cryoglobulin measurement before and after DAA
Exclusion criteria
\-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cryoglobulin level at the end of therapy | End of treatment (12 or 24 weeks) | The primary outcome was the cryoglobulin level at the end of direct-acting antiviral treatment (week 12 or 24 according to treatment duration) |
Countries
France
Outcome results
None listed